Anemia during treatment with peginterferon Alfa‐2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT‐2) trial
Mark S. Sulkowski, Fred Poordad, Michael P. Manns, Jean‐Pierre Bronowicki, K. Rajender Reddy, Stephen A. Harrison, Nezam H. Afdhal, Heather L. Sings, Lisa D. Pedicone, Kenneth J. Koury, Vilma Sniukiene, Margaret H. Burroughs, Janice K. Albrecht, Clifford A. Brass, Ira M. Jacobson, for the SPRINT‐2 Trial Investigators – 18 October 2012 – Boceprevir (BOC) added to peginterferon alfa‐2b (PegIFN) and ribavirin (RBV) significantly increases sustained virologic response (SVR) rates over PegIFN/RBV alone in previously untreated adults with chronic hepatitis C genotype 1.